Segui
Stefano Persiani
Stefano Persiani
Director Translational Sciences and Pharmacokinetics
Email verificata su rottapharmbiotech.com
Titolo
Citata da
Citata da
Anno
Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis
VB Kraus, B Burnett, J Coindreau, S Cottrell, D Eyre, M Gendreau, ...
Osteoarthritis and Cartilage 19 (5), 515-542, 2011
3082011
Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man
S Persiani, E Roda, LC Rovati, M Locatelli, G Giacovelli, A Roda
Osteoarthritis and Cartilage 13 (12), 1041-1049, 2005
2212005
Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
S Persiani, R Rotini, G Trisolino, LC Rovati, M Locatelli, D Paganini, ...
Osteoarthritis and Cartilage 15 (7), 764-772, 2007
1702007
Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties
LC Rovati, F Girolami, S Persiani
Therapeutic Advances in Musculoskeletal Disease 4 (3), 167-180, 2012
832012
Development and validation of a sensitive HPLC–ESI-MS/MS method for the direct determination of glucosamine in human plasma
A Roda, L Sabatini, A Barbieri, M Guardigli, M Locatelli, FS Violante, ...
Journal of Chromatography B 844 (1), 119-126, 2006
742006
OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis
VB Kraus, FJ Blanco, M Englund, Y Henrotin, LS Lohmander, E Losina, ...
Osteoarthritis and Cartilage 23 (5), 686-697, 2015
692015
Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in …
AC Andreotti, E Pianezzola, S Persiani, MA Pacciarini, M Strolin Benedetti, ...
The Journal of Clinical Endocrinology & Metabolism 80 (3), 841-845, 1995
681995
Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers
G Fornasini, N Monti, G Brogin, M Gallina, M Eandi, S Persiani, M Bani, ...
Chirality 9 (3), 297-302, 1997
401997
Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide
F Formelli, E Cavadini, R Luksch, A Garaventa, MG Villani, V Appierto, ...
Cancer chemotherapy and pharmacology 62 (4), 655-665, 2008
342008
Transcellular processing of disulfide‐and thioether‐linked peroxidase‐polylysine conjugates in cultured MDCK epithelial cells
J Wan, S Persiani, WC Shen
Journal of cellular physiology 145 (1), 9-15, 1990
321990
Polylysine conjugates of Bowman–Birk protease inhibitor as targeted anti-carcinogenic agents
S Persiani, A Yeung, WC Shen, AR Kennedy
Carcinogenesis 12 (6), 1149-1152, 1991
301991
Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay
S Persiani, F Broutin, P Cicioni, P Stefanini, MS Benedetti
European journal of pharmaceutical sciences 4 (6), 331-340, 1996
291996
Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake.
T Piepoli, T Zanelli, O Letari, S Persiani, LC Rovati, G Caselli
ARTHRITIS AND RHEUMATISM 52 (9), S502-S503, 2005
282005
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
G Caselli, A Bonazzi, M Lanza, F Ferrari, D Maggioni, C Ferioli, ...
Arthritis research & therapy 20 (1), 1-19, 2018
272018
Development and validation of a HPLC–ES-MS/MS method for the determination of glucosamine in human synovial fluid
E Pastorini, R Rotini, M Guardigli, S Vecchiotti, S Persiani, G Trisolino, ...
Journal of Pharmaceutical and Biomedical Analysis 50 (5), 1009-1014, 2009
272009
Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients.
S Persiani, R Rotini, G Trisolino, L Delliponti, LC Rovati, M Locatelli, ...
ARTHRITIS AND RHEUMATISM 52 (9), S508-S508, 2005
272005
A double‐blind, placebo‐controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor …
M Bani, A Colantoni, M Guillaume, F Macchi, G Moroni, S Persiani
British journal of clinical pharmacology 50 (4), 338-349, 2000
262000
Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers
S Persiani, G Sassolas, G Piscitelli, CA Bizollon, I Poggesi, E Pianezzola, ...
Journal of pharmaceutical sciences 83 (10), 1421-1424, 1994
261994
Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors
M Biava, C Battilocchio, G Poce, S Alfonso, S Consalvi, A Di Capua, ...
Bioorganic & medicinal chemistry 22 (2), 772-786, 2014
222014
Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients
S Persiani, M D'Amato, F Makovec, SH Arshad, ST Holgate, LC Rovati
Biopharmaceutics & drug disposition 22 (2), 73-81, 2001
212001
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20